2023
Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
McNamara B, Bellone S, Demirkiran C, Hartwich T, Santin A. Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy. Gynecologic Oncology Reports 2023, 48: 101218. PMID: 37325296, PMCID: PMC10265468, DOI: 10.1016/j.gore.2023.101218.Peer-Reviewed Original ResearchOvarian clear cell carcinomaClear cell carcinomaCombination of pembrolizumabCell carcinomaTreatment optionsRecurrent ovarian clear cell carcinomaWeeks of therapyCT scan findingsMild side effectsEffective treatment optionOral multikinase inhibitorNew treatment optionsDurable responsesMetastatic diseaseScan findingsPD-1Disease burdenTarget lesionsMultikinase inhibitorDrug combinationsSide effectsPembrolizumabLenvatinibMonoclonal antibodiesCarcinoma
2022
Immune checkpoint inhibitors for recurrent endometrial cancer
Mutlu L, Harold J, Tymon-Rosario J, Santin AD. Immune checkpoint inhibitors for recurrent endometrial cancer. Expert Review Of Anticancer Therapy 2022, 22: 249-258. PMID: 35176955, DOI: 10.1080/14737140.2022.2044311.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsRecurrent endometrial cancerCheckpoint inhibitorsEndometrial cancerEC patientsAdvanced/recurrent endometrial cancerPD-1/PD-L1 inhibitorsRecurrent EC patientsUse of chemotherapyCommon gynecologic malignancyMajor clinical trialsPD-L1 inhibitorsBiomarkers of responseViable treatment optionHuman cancer treatmentTumor microenvironment immunosuppressionRecurrent diseaseGynecologic malignanciesPD-1Clinical efficacyPatient populationTreatment optionsTumor immunogenicityRecent trialsClinical trials
2018
A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer.
Santin A, Deng W, Frumovitz M, Huh W, Khleif S, Lankes H, Ratner E, O'Cearbhaill R, Jazaeri A, Birrer M. A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer. Journal Of Clinical Oncology 2018, 36: 5536-5536. DOI: 10.1200/jco.2018.36.15_suppl.5536.Peer-Reviewed Original Research
2016
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro
Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology 2016, 144: 146-152. PMID: 27894751, PMCID: PMC5183545, DOI: 10.1016/j.ygyno.2016.11.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCarboplatinCarcinomaCD4 Lymphocyte CountCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell SurvivalDisease-Free SurvivalDNA Polymerase IIDrug Resistance, NeoplasmEndometrial NeoplasmsFemaleHumansMicrosatellite InstabilityMiddle AgedMutationPoly-ADP-Ribose Binding ProteinsTumor Cells, CulturedConceptsBetter prognosisTumor cell linesInfiltration of CD4Number of CD4Platinum-based chemotherapyT lymphocyte infiltrationPD-1 receptorCell linesLow metastatic capabilityPOLE-mutated tumorsWild-type ECsEC cell linesLymphocyte infiltrationFavorable prognosisPD-1EC patientsType tumorsEnhanced immunogenicityT lymphocytesMolecular subtypesTumors correlatesChemotherapyMetastatic capabilityPrognosisTumorsImmune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers
Menderes G, Hicks C, Black JD, Schwab CL, Santin AD. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. Expert Opinion On Biological Therapy 2016, 16: 989-1004. PMID: 27070175, DOI: 10.1080/14712598.2016.1177018.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCytotoxic T-lymphocyte antigen-4Checkpoint inhibitorsGynecologic cancer patientsGynecologic cancerCancer patientsImmune responseT-lymphocyte antigen-4Non-gynecologic cancersEffective cancer immunotherapyLong-term remissionCheckpoint inhibitor immunotherapySurvival of patientsCancer cellsImmunotherapeutic researchAnticancer immunityPD-1Advanced cancerImmunotherapeutic agentsTreatment regimensAntigen-4Cancer immunotherapyClinical activityClinical experienceImmunotherapy